TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03211936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP TITRATED
Description: After titrated peep levels, we choice this level of peep for de group (peep titrated)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP TITRATED
Description: After titrated peep levels, we choice this level of peep for de group (peep titrated)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use ultrasound
Description: We make a lung ultrasound after we setup a different level of PEEP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use ultrasound
Description: We make a lung ultrasound after we setup a different level of PEEP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impedance tomography
Description: We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impedance tomography
Description: We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best PEEP for less collapse
Description: After titrated PEEP levels we setup the best PEEP the according of tomography impedance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEEP 4
Description: We set the peep level after titrated peep = 4 cmH20.
Study: NCT02546245

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heroes of Knowledge
Description: Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
Study: NCT05799365

Intervention type: OTHER
Intervention: GMFCS-FR Turkish Adaptation
Description: GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.

Intervention type: OTHER
Intervention: GMFCS-FR Turkish Adaptation
Description: GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.

Intervention type: OTHER
Intervention: GMFCS-FR Turkish Adaptation
Description: GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
Study: NCT02546245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention/Time Control Game
Description: Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
Study: NCT01785589

Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronary angiography
Description: A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
Study: NCT01100463

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream
Description: Twice daily lotion to prevent HFS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% Uracil Cream
Description: Twice daily lotion to prevent HFS
Study: NCT01754558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ajust system
Description: The use of Ajust system for stress incontinence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ajust system
Description: The use of Ajust system for stress incontinence
Study: NCT02741752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decortication
Description: cortical bone perforation
Study: NCT00448630

Intervention type: OTHER
Intervention: No intervention
Description: Non-interventional study
Study: NCT04428060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PERSEUS CPR
Description: Resuscitation based on patient physiology

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR
Description: Resuscitation based on current guidelines
Study: NCT03991065

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: high digestive endoscopy
Description: high digestive endoscopy with biopsies performed according to the sydney protocol
Study: NCT04608656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of livestock feeds
Description: Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provision of livestock feeds
Description: Households will receive livestock feeds (ranch cubes) for the select lactating animals during the dry season

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition counselling
Description: Households will receive livestock feeds (ranch cubes) for the select lactating animals and will also be enrolled in to a nutrition counselling programme
Study: NCT00003692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic thoracoscopy
Study: NCT01754558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT/TVT-O
Description: sling surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TVT/TVT-O
Description: sling surgery
Study: NCT01057212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
Study: NCT00003692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted surgery
Study: NCT01057212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
Study: NCT01267071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: GSK962040 (50 mg, SD, oral)
Study: NCT01890122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and Metformin FDC Placebo
Description: Alogliptin and metformin FDC placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and Metformin FDC Placebo
Description: Alogliptin and metformin FDC placebo-matching tablets
Study: NCT01267071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: GSK962040 (50 mg, SD, oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B
Description: 14C GSK962040 (100 μg, SD, iv)
Study: NCT01070875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variation of heparin dose
Description: Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
Study: NCT01652573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nasal salmon calcitonin
Description: 400 IU daily in two sprays (one to each nares)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray Placebo
Study: NCT01906580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: 180ug peg-IFNα-2a, subcutaneous injection per week
Study: NCT02684942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT01070875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Variation of heparin dose
Description: Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
Study: NCT03565718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention: Restaurant
Description: Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to local vegan soul food restaurants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention: Standard/Grocery
Description: Participants will receive instruction on how to follow a vegan diet for three weeks and will receive gift cards to grocery stores.
Study: NCT03056846

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Combination
Description: A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum
Description: A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum
Description: A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
Study: NCT01181921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
Study: NCT04621305

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bolus Remimazolam
Description: Anesthesia is maintained by sevoflurane and continuous infusion of normal saline(1ml/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2mg/kg remimazolam is administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Infusion Remimazolam
Description: Anesthesia is maintained by sevoflurane and continuous infusion of remimazolam(1mg/kg/h) is administered until about 5min before the end of the surgery. Then intravenous bolus of 0.2ml/kg normal saline is administered.
Study: NCT01841749

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sentinel node biopsy and mastectomy
Description: sentinel node biopsy and mastectomy
Study: NCT01906580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: 180ug peg-IFNα-2a, subcutaneous injection per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFNα-2a
Description: 180ug peg-IFNα-2a, subcutaneous injection per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg,oral administration every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: 0.5mg,oral administration every day
Study: NCT03179956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Treatment with ribociclib \[600mg\] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
Study: NCT02913261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Description: Ruxolitinib was provided as 5 mg tablets for oral use.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy (BAT)
Description: BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Study: NCT02558660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational intervention about an existing SNAP healthy food incentive program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: voucher
Description: $10 voucher to spend on produce at farmers markets
Study: NCT02684942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT03574454

Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning (ML)
Description: Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma

Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning (ML)
Description: Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma

Intervention type: OTHER
Group type: OTHER
Intervention: Machine Learning (ML)
Description: Application of ML support algorithm to accelerate and enhance human interpretation of WB-MRI scans in patients with myeloma
Study: NCT03200392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser root surface conditioning & laser DGG harvesting
Description: laser root surface bio-modification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser root surface conditioning & blade DGG harvesting
Description: laser root surface bio-modification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blade DGG harvesting
Description: De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
Study: NCT02139501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombopoietin (rhTPO)
Description: rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombopoietin (rhTPO)
Description: rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thrombopoietin (rhTPO)
Description: rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
Study: NCT01219738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 360ug
Description: A single inhaled dose of 360ug budesonide from a DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 720ug
Description: A single inhaled dose of 720ug budesonide from a DPI.
Study: NCT01578252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Tablets USP 8 mg
Description: 8 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron Hydrochloride
Description: 8 mg tablet once a day
Study: NCT01823237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study: NCT01219738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 1440ug
Description: A single dose of 1440ug of the budesonide from DPI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide720ug 4 times
Description: 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
Study: NCT02214017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A videotelephone, TandBerg E20,
Study: NCT01823237

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Study: NCT04591600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin and Doxycyline
Description: Ivermectin 200ug/kg PO per day for two days, and in some patients who needed more time to recover, a third dose 200ug/kg PO per day was given 7 days after the first dose. Doxycycline 100mg capsule PO every 12h per day was given for 5-10 days, based on the clinical improvement of patients. In addition, standard care was given to the patients of Ivermectin-Doxycycline group based on the clinical condition of each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard care~* Acetaminophen 500mg on need~* Vitamin C 1000mg twice/ day~* Zinc 75-125 mg/day~* Vitamin D3 5000IU/day~* Azithromycin 250mg/day for 5 days~* Oxygen therapy/ C-Pap if needed~* dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed~* Mechanical ventilation, if needed
Study: NCT02107963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2-CAR engineered T cells
Description: Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GD2-CAR engineered T cells
Description: Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1800mg/m2/d X 2 days as a lymphodepleting regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1800mg/m2/d X 2 days as a lymphodepleting regimen
Study: NCT04164394

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment (maltodextrin), once daily (u.i.d)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: I31 Probiotic
Description: I31 probiotic formula (dietary supplement), consisting of 3 billion cfus of strains P. acidilactici CECT7483, L.plantarum CECT7484 and L.plantarum CECT7485, once daily (u.i.d)
Study: NCT00660049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SNaP Advanced Wound Care System
Description: Application of negative pressure device daily per instructions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNaP
Description: Daily use

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNaP
Description: Daily application per protocol
Study: NCT01649245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reiferon retard
Description: Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is \>75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
Study: NCT02795949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antipseudomonal beta-lactam antibiotic
Description: Pharmaceutical form: solution for infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: De-escalation(short-spectrum antibiotic)
Description: Pharmaceutical form: solution for infusion
Study: NCT00484120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3%-Diclofenac-Nano-Emulsion Cream
Description: 3%-Diclofenac-Nano-Emulsion Cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream